Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9W2F

Cryo-EM structure of DDB1-CRBN in complex with dHuR-2 and HuR

This is a non-PDB format compatible entry.
Summary for 9W2F
Entry DOI10.2210/pdb9w2f/pdb
EMDB information65569
DescriptorDNA damage-binding protein 1, Protein cereblon, ELAV-like protein 1, ... (5 entities in total)
Functional Keywordsmolecular glue degrader, complex, rna binding protein
Biological sourceHomo sapiens (human)
More
Total number of polymer chains3
Total formula weight180844.39
Authors
Dou, H.,Zhu, Y. (deposition date: 2025-07-27, release date: 2026-04-22, Last modification date: 2026-06-24)
Primary citationLu, X.,Wang, X.,Yang, Z.,Wang, X.,Wang, L.,Xu, C.,Lo, I.C.,Geng, C.,Wang, L.,Pu, Y.,Zhang, K.,Zhu, Z.,Ye, L.,Huang, J.,Wei, X.,Bai, F.,Zhu, Y.,Qian, X.,Dou, H.,Su, H.,Cang, Y.
Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer.
Nature, 2026
Cited by
PubMed Abstract: BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all patients with colorectal cancer (CRC), and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as encorafenib are ineffective due to MAPK pathway reactivation driven by BRAF dimerization. Combined inhibition of BRAF and EGFR, although approved therapies, results in short survival benefits and frequent treatment resistance and relapse. Here, through rational chemical library design coupled with parallel proteomic screening, we identified dHuR as a molecular glue degrader of human antigen R (HuR), an RNA-binding protein that drives tumour growth, invasion and therapy resistance. dHuR binds to the CRBN ubiquitin ligase to create a unique benzofuran-tethered composite surface to recruit HuR as a neosubstrate by engaging its β-hairpin G-loop degron, as revealed by the cryo-electron microscopy structure of the ternary complex. dHuR abrogated BRAF expression by inducing its exon 18 skipping, and demonstrated superior suppression of BRAF-mutant CRC tumours including those gaining resistance to BRAF inhibitors. Finally, we performed kinome library CRISPR screening and revealed that inactivation of EGFR or MEK enhanced dHuR cytotoxicity, thus establishing a combinatorial strategy to treat patients with refractory BRAF-mutant CRC.
PubMed: 42271059
DOI: 10.1038/s41586-026-10613-5
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (3.4 Å)
Structure validation

255900

PDB entries from 2026-07-01

PDB statisticsPDBj update infoContact PDBjnumon